Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9871152 | 1.00 | L3MBTL3 (0.42) | L3MBTL3HRH3DRD3DRD2CYP2D6 | |
| SCHEMBL27282631 | 1.00 | L3MBTL3 (0.42) | L3MBTL3HRH3DRD3DRD2CYP2D6 | |
| SCHEMBL30379435 | 0.89 | GNAI3 (0.41) | L3MBTL3DRD3DRD2DRD1DRD4 | |
| SCHEMBL9869321 | 0.89 | GNAI3 (0.41) | L3MBTL3DRD3DRD2DRD1DRD4 | |
| SCHEMBL13167818 | 0.88 | HRH3 (0.45) | HRH3DRD2 | |
| SCHEMBL6920677 | 0.87 | GNAO1 (0.47) | DRD3DRD2DRD1DRD4DRD5 | |
| SCHEMBL17351087 | 0.85 | GNAO1 (0.50) | DRD3DRD2DRD1DRD4DRD5 | |
| SCHEMBL24661958 | 0.83 | — | — | |
| SCHEMBL24662678 | 0.83 | — | — | |
| SCHEMBL9870758 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081311-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2024-04-18 | — | — | WO | disclosed |